Fatty liver disease, also called metabolic dysfunction-associated steatohepatitis (MASH), is a condition where fat ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

Weekly 2.4 mg semaglutide was linked to improved liver histology results but did not significantly reduce body pain compared ...

GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening ...

A game-changing medication known for diabetes and weight loss might also hold the key to improving liver health for millions of Americans.

Discover how metabolic dysfunction-associated steatohepatitis (MASH) damages your liver, its connection to common health ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Novo Nordisk’s Wegovy (semaglutide injection) 2.4mg has demonstrated early protection against heart disease, according to new ...

Patients lost an average of 18.4 centimeters around their waists on Zepbound and 13 centimeters on Wegovy. Belly fat is ...

Two patients with MASH share their paths to diagnosis, including the challenges they faced and what it took to find answers.